Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of SKI-O-703 in Healthy Adults
NCT07675226Phase 1Active, not recruiting
- Sponsor
- Oscotec Inc.
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cevidoplenib in immune thrombocytopenia (ITP) and rheumatoid arthritis (RA) (2 arms), sponsored by Oscotec Inc. Primary endpoints: Area Under the Curve from Time Zero to the Last Quantifiable Concentration at 1 year and Maximum Observed Plasma Concentration at 1 year. Started Jul 2026; status: active, not recruiting.
02
Drugs
cevidoplenib
03
Conditions
immune thrombocytopenia (ITP)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07675226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07675226.